Subscribe
shutterstock_1492764635_michael_vi
Michael Vi / Shutterstock.com
4 February 2021Big PharmaAlex Baldwin

Coherus secures toripalimab rights for US and Canada

Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.

More on this story

Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool